ZA942597B - Inhibition control and regression of angiogenesis - Google Patents

Inhibition control and regression of angiogenesis

Info

Publication number
ZA942597B
ZA942597B ZA942597A ZA942597A ZA942597B ZA 942597 B ZA942597 B ZA 942597B ZA 942597 A ZA942597 A ZA 942597A ZA 942597 A ZA942597 A ZA 942597A ZA 942597 B ZA942597 B ZA 942597B
Authority
ZA
South Africa
Prior art keywords
hyaluronic acid
angiogenesis
pharmaceutical composition
regression
amount
Prior art date
Application number
ZA942597A
Other languages
English (en)
Inventor
Derek A Willoughby
Chandan Alam
Samuel Simon Asculai
Rudolf Edgar Falk
David William Harper
Original Assignee
Norpharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norpharmco Inc filed Critical Norpharmco Inc
Priority to TW083104576A priority Critical patent/TW316236B/zh
Publication of ZA942597B publication Critical patent/ZA942597B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Filters For Electric Vacuum Cleaners (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Cephalosporin Compounds (AREA)
ZA942597A 1993-04-16 1994-04-15 Inhibition control and regression of angiogenesis ZA942597B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW083104576A TW316236B (de) 1994-04-11 1994-05-20

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002094203A CA2094203A1 (en) 1993-04-16 1993-04-16 Inhibition of angiogenesis
CN94192096A CN1123005A (zh) 1993-04-16 1994-04-15 用于抑制、控制和消退血管生成的含有透明质酸和nsaid的组合物

Publications (1)

Publication Number Publication Date
ZA942597B true ZA942597B (en) 1995-02-08

Family

ID=37089291

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA942597A ZA942597B (en) 1993-04-16 1994-04-15 Inhibition control and regression of angiogenesis

Country Status (18)

Country Link
EP (1) EP0695187B1 (de)
JP (1) JPH08508505A (de)
CN (1) CN1123005A (de)
AT (1) ATE226827T1 (de)
AU (2) AU694113B2 (de)
BR (1) BR9405781A (de)
CA (1) CA2094203A1 (de)
CZ (1) CZ267995A3 (de)
DE (1) DE69431623D1 (de)
FI (1) FI954914A (de)
HU (2) HUT74462A (de)
IL (1) IL109293A (de)
NO (1) NO954073L (de)
PL (1) PL306806A1 (de)
SG (1) SG48924A1 (de)
SK (1) SK126595A3 (de)
WO (1) WO1994023725A1 (de)
ZA (1) ZA942597B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
DK1586322T3 (da) * 1996-11-05 2008-12-01 Childrens Medical Center Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer
WO1998042329A1 (fr) * 1997-03-21 1998-10-01 Mitsubishi Chemical Corporation Preventifs et/ou remedes destines a des affections provoquees par une neovascularisation anormale
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
JP4790911B2 (ja) 1999-01-13 2011-10-12 アルケミア オンコロジー ピーティワイ リミテッド 薬物の効力を増強するための組成物および方法
JP4587148B2 (ja) * 2000-03-24 2010-11-24 生化学工業株式会社 平滑筋細胞増殖促進剤
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
ITPD20020003A1 (it) * 2002-01-11 2003-07-11 Fidia Advanced Biopolymers Srl Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori.
ITMI20040347A1 (it) * 2004-02-26 2004-05-26 Pharma Medical Ltd Nuovo farmaco di associazione
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EA013877B1 (ru) 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
EA015702B1 (ru) * 2007-05-28 2011-10-31 Винченцо Массимо Ломбардо Противовоспалительная и анальгетическая композиция для местного применения в области опорно-двигательного аппарата животного
EP2567697A1 (de) * 2011-09-12 2013-03-13 Almirall, S.A. Topische pharmazeutische Zusammensetzungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids

Also Published As

Publication number Publication date
NO954073D0 (no) 1995-10-13
FI954914A0 (fi) 1995-10-16
CZ267995A3 (en) 1996-10-16
IL109293A (en) 1999-01-26
FI954914A (fi) 1995-11-06
PL306806A1 (en) 1995-04-18
JPH08508505A (ja) 1996-09-10
EP0695187B1 (de) 2002-10-30
CN1123005A (zh) 1996-05-22
HU211954A9 (en) 1996-01-29
AU6994198A (en) 1998-07-23
NO954073L (no) 1995-12-04
HUT74462A (en) 1996-12-30
AU6561694A (en) 1994-11-08
WO1994023725A1 (en) 1994-10-27
IL109293A0 (en) 1994-07-31
AU694113B2 (en) 1998-07-16
CA2094203A1 (en) 1994-10-17
DE69431623D1 (de) 2002-12-05
SK126595A3 (en) 1997-03-05
HU9500113D0 (en) 1995-03-28
ATE226827T1 (de) 2002-11-15
BR9405781A (pt) 1996-01-16
SG48924A1 (en) 1998-05-18
EP0695187A1 (de) 1996-02-07

Similar Documents

Publication Publication Date Title
ZA942597B (en) Inhibition control and regression of angiogenesis
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
BR9814389A (pt) Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
ES8500743A1 (es) Procedimiento para preparar formas de mopidamol como granulados, granulos o tabletas
CA2125662A1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
HUT73433A (en) Process for preparing pharmaceutical compositions containing riluzole for treating aids-related neural disorders
CA2283399A1 (en) Pyridazinones as inhibitors of cyclooxygenase-2
WO1993007866A3 (en) Compositions and methods for therapy and prevention of cancer, aids, and anemia
ES2100222T3 (es) Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas.
ZA926148B (en) Therapeutic compounds
EP0412940A3 (en) Hydantoin or imidazolidinetrione derivatives for the prevention or treatment of renal failure
EP0838223A4 (de) Ein inhibitor für das gehirnödem
CA2198580A1 (en) Combination therapy to treat osteoporosis
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
AU4777293A (en) Control of wound scar production with calcium antagonists alone or in a combination with a steroid
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
HK1009325A1 (en) Composition comprising l-carnitine or acyl-l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders
NZ514425A (en) Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
MX9805317A (es) Agente para la profilaxis y el tratamiento de complicaciones diabeticas.
IT1293583B1 (it) Uso dell'acido gammaidrossibutirrico per il trattamento delle sindromi demenziali
ES2065855A1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
HU9402698D0 (en) Pharmaceutical composition for treating climacteric osteoporosis
WO1999027921A3 (en) Compositions and methods for modulating the activity of fibroblast growth factor
EP0384302A3 (de) Verwendung von Ubenimex zur Hestellung eines Medikaments zur Behandlung des myelodysplastischen Syndroms
ES2136018A1 (es) Compuestos inhibidores selectivos de la ciclooxigenasa-i y su utilizacion como analgesicos, antiinflamatorios y antiartriticos.